Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-10-20 00:00:00 ET · period of report 2023-10-18 · accession 0001209191-23-053251 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-10-20 | 2023-10-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | S - Sale+OE | $45.92 | -8,000 | 79.5K | -9% | -$367.3K |
| D | 2023-10-20 | 2023-10-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $5.35 | +8,000 | 87.5K | +10% | +$42.8K |
| D | 2023-10-20 | 2023-10-18 | PCVX | GUGGENHIME ANDREW | Pres, CFO | M - OptEx | $0.00 | -8,000 | 422.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-18 | S | D | 7,497 | $45.89 | 79,977 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $45.295 to $46.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2023-10-18 | S | D | 503 | $46.32 | 79,474 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $46.29 to $46.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2023-10-18 | M | A | 8,000 | $5.35 | 87,474 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2023-10-18 | M | D | 8,000 | $0.00 | 422,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |